TREATMENT OF CHRONIC LYMPHOCYTIC B-LEUKEMIA (B-CLL) WITH HUMAN IL-2 AND CD40

用人 IL-2 和 CD40 治疗慢性淋巴细胞 B 白血病 (B-CLL)

• 批准号: 7375044
• 负责人: MALCOLM K. BRENNER
• 金额: $ 2.64万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375044
• 关键词: TREATMENT; CHRONIC; LYMPHOCYTIC; LEUKEMIA; CLL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is proposed that the ability of CD40 Ligand (CD40L) to enhance leukemia antigen presentation in vivo, to act as a co-stimulator molecule and to induce hIL-2 release all serve to recruit both specific T cell and NK cell anti-leukemia effector mechanisms, which hIL-2 is then able to further amplify. The specific aims of the study are: 1) To determine the safety of three to six subcutaneous (SC) injections of autologous malignant B cells from chronic lymphocytic leukemia (B-CLL) patients, which have been modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L; 2) To determine whether MHC-restricted or unrestricted anti-tumor immune responses are induced by SC injections of B-CLL cells which have been modified ex vivo to secrete hIL-2 and to express hCD40L; and 3) To obtain preliminary data on the anti-timor effects of this treatment regimen.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。我们提出CD40配体（CD40L）在体内增强白血病抗原呈递、作为共刺激分子和诱导il -2释放的能力都有助于招募特异性T细胞和NK细胞抗白血病效应机制，然后il -2能够进一步扩增。该研究的具体目的是：1)确定慢性淋巴细胞白血病（B- cll）患者的自体恶性B细胞皮下注射3至6次的安全性，这些细胞在体外被修饰为分泌人白细胞介素-2 （il -2）并表达人CD40配体(hCD40L；2) SC注射经体外修饰分泌hIL-2和表达hCD40L的B-CLL细胞是否诱导mhc限制性或非限制性抗肿瘤免疫反应；3)获得该治疗方案抗帝汶效果的初步数据。